YEWB — Stock Film
STOCK FILMSCENE 1/11YEWB · $0.0002
Stock Expert AI presents
YEWB
Yew Bio-Pharm Group, Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Yew Bio-Pharm Group, Inc. A quick introduction.

On the stock market since 2013, it operates in the everyday-essentials business. It has 35 employees. Now — the numbers.

on the stock market since 2013
35 employees
$12K market value
Revenue last year:
$0
The net profit left over:
$0
Out of every $100 in sales, $5 stays as net profit.
THE SLICE THAT TURNS INTO PROFIT: 5%

This is an established company with proven profits.

WHERE DOES THE MONEY COME FROM?
50%All Other
All Other 50%Tcm Raw Materials 50%Handicrafts <1%Yew Trees <1%
50% of all revenue comes from a single line: All Other.

The biggest line carries real weight, but it doesn’t decide everything on its own.

THE SALES TREND
Sales have been shrinking.

An average decline of 15% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.

$51.3M
2016
$40.5M
2017
$37.6M
2018
$27.9M
2019
$27.3M
2020
Cash on hand:
$0
Total debt:
$0
The debt outweighs the cash.

The gap is $8.8M. In times of high interest rates, a gap like that can squeeze a company.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 3 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

WEAK SPOTS
The stock has lost its spark0/10
Growth has stalled2/10
Thin profit on each sale3/10
WORTH WATCHING

Revenue Growth: Sales are growing slowly.

THE FIVE-YEAR JOURNEY
A big climb, then a hard fall.

An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

THE BRIGHT SIDE

Nothing in the current numbers stands out as a strong positive. That, by itself, is worth knowing.

1
THE RISKS · 1/3
Trading under $1

The stock sits at $0.0002. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.

2
THE RISKS · 2/3
Sales are shrinking

Over the last 3 years, sales fell about 12% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.

3
THE RISKS · 3/3
Executives lean toward selling

Over the last 12 months, executives reported 32 sells against just 3 buys. Not an alarm bell by itself, but a number worth watching.

FINALE · THE GRADE
D
0 / 100 · MoonshotScore

On our five-subject report card, YEWB sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: YEWB is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Aug 21, 2026 · stockexpertai.com · Stock Film